Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center

Brian Rush, Olivia Marcus, Sara Mallén García, Anja Loizaga-Velder, Gabriel Loewinger, Ariane Spitalier, Fernando MendiveFrontiers in Pharmacology 2021 · DOI

Introduction

The global landscape of addiction treatment is facing a crisis of efficacy, characterized by high relapse rates and limited accessibility to effective long-term care. In response, interest has surged in traditional medicines, particularly the Amazonian psychedelic brew known as ayahuasca. However, scientific research has often struggled to bridge the gap between the "molecule" (DMT) and the "model" (the complex ritual and therapeutic setting). This paper, published in Frontiers in Pharmacology, details the research protocol for the Ayahuasca Treatment Outcome Project (ATOP), specifically focusing on its implementation at the Takiwasi Center in Peru.

The Research Challenge: Beyond the Molecule

Mainstream addiction medicine frequently treats substance use disorders (SUD) through a lens of neurobiology. While this has led to important pharmacological interventions, it often overlooks the socio-cultural and psychological contexts that practitioners of traditional medicine believe are vital for recovery. The ATOP protocol addresses the need for a rigorous, standardized framework to evaluate "complex interventions"—treatments where the outcome is driven by multiple interacting components rather than a single active ingredient.

The authors argue that studying ayahuasca in a sterile laboratory setting strips away the "set and setting" that are foundational to its traditional use. To capture the true efficacy of these practices, a "naturalistic" approach is required—one that observes the treatment as it is delivered in its native environment.

Methodology: A Mixed-Methods Approach

The ATOP protocol utilizes a prospective longitudinal cohort design. Unlike a Randomized Controlled Trial (RCT), which might exclude the very patients most likely to seek this treatment, this naturalistic study tracks patients through their actual journey at the Takiwasi Center.

Quantitative Tracking

Patients are assessed at multiple time points: intake, discharge, and at 3, 6, 12, 18, and 24 months post-treatment. The study employs a battery of internationally recognized standardized tools:

  • Addiction Severity Index (ASI-5): To measure the impact of SUD across various life domains.
  • Global Appraisal of Individual Needs (GAIN-I): For comprehensive clinical assessment.
  • Beck Depression and Anxiety Inventories (BDI/BAI): To track comorbid mental health symptoms.
  • WHOQOL-BREF: To assess changes in the overall quality of life.

Qualitative Depth

To understand why and how the treatment works, semi-structured interviews are conducted with patients, clinical staff, and traditional healers. These interviews aim to capture the subjective meaning patients derive from their experiences, particularly during ayahuasca ceremonies.

Statistical Innovation

Handling the high number of variables inherent in a complex residential setting presents a statistical challenge. To mitigate the risk of "Type I" errors (false positives), the researchers utilize Directed Acyclic Graphs (DAGs). These conceptual models allow researchers to map hypothesized relationships between variables before conducting multivariate regression analyses, ensuring that the statistical findings are grounded in a coherent theoretical framework.

The Takiwasi Model: The "Therapeutic Tripod"

The Takiwasi Center serves as the primary study site for ATOP. Its model is built on a "therapeutic tripod" that integrates three distinct but overlapping domains:

  1. Traditional Amazonian Medicine: This includes the use of purgative plants, "dietas" (periods of isolation and specific food restrictions), and ayahuasca ceremonies led by experienced healers.
  2. Modern Psychotherapy: Individual and group therapy sessions help patients integrate their psychedelic experiences and address the psychological roots of their addiction.
  3. Community Living: The residential nature of the program fosters a "therapeutic community" where shared labor, social support, and communal living play a critical role in rehabilitation.

In this model, the ritual environment—the maloca (ceremonial house), the icaros (healing songs), and the presence of the healer—are viewed as "active ingredients" rather than background noise.

Preliminary Findings and Protocol Feasibility

As a protocol paper, the primary goal is to establish the feasibility of the research design. Preliminary data from the Takiwasi site revealed:

  • Recruitment and Attrition: Of the initial 128 participants who completed intake, approximately 32.8% left the program before their first ayahuasca ceremony. While high, this attrition rate is consistent with other long-term residential SUD programs and highlights the intensive nature of the Takiwasi model.
  • Follow-up Success: For those who reached the one-year mark, the study achieved an 80% completion rate for follow-up interviews. This suggests that the protocol is sustainable for long-term tracking, a common hurdle in addiction research.

Limitations and Future Directions

The authors acknowledge several limitations inherent in naturalistic research. Selection bias is a primary concern, as participants are self-selected and may possess higher levels of motivation than the general SUD population. Additionally, the chemical variability of ayahuasca—a biological brew whose alkaloid content can vary between batches—is not currently analyzed for every dose.

The lack of a randomized control group makes it difficult to isolate the specific effect of ayahuasca from the broader residential setting. However, the ATOP protocol is designed as an "umbrella" project. By replicating this methodology at other sites, such as the Nierika Center in Mexico, researchers hope to synthesize data across different cultural and clinical contexts to identify the universal mechanisms of psychedelic-assisted recovery.

Conclusion

The ATOP protocol represents a significant step forward in psychedelic science. By moving beyond the "black box" of residential care and embracing the complexity of traditional healing systems, this research aims to provide a robust evidence base for integrative addiction treatments. As the project expands, it promises to offer deep insights into how the synergy of ancient wisdom and modern science can address one of society's most persistent health challenges.

Summary updated

Abstract

The present study describes the protocol for the Ayahuasca Treatment Outcome Project (ATOP) with a special focus on the evaluation of addiction treatment services provided through Takiwasi Center, the first ATOP study site. The goal of the project is to assess treatment outcomes and understand the therapeutic mechanisms of an Ayahuasca-assisted, integrative treatment model for addiction rehabilitation in the Peruvian Amazon. The proposed intervention protocol highlights the significance of treatment setting in the design, delivery, and efficacy of an addiction rehabilitation program that involves the potent psychedelic tea known as Ayahuasca. After describing the context of the study, we put forth details about our mixed-methods approach to data collection and analysis, with which we seek to gain an understanding of why, how, and for whom this specific ayahuasca-assisted treatment program is effective across a range of outcomes. The ATOP protocol employs qualitative research methods as a means to determine which aspects of the setting are meaningful to clients and practitioners, and how this may correlate with outcome measures. This paper delineates the core principles, methods, and measures of the overall ATOP umbrella, then discusses the role of ATOP in the context of the literature on long-term residential programs. To conclude, we discuss the strengths and limitations of the protocol and the intended future of the project.
BibTeX
@inproceedings{rush2021protocol,
  author = {Brian Rush and Olivia Marcus and Sara Mallén García and Anja Loizaga-Velder and Gabriel Loewinger and Ariane Spitalier and Fernando Mendive},
  title = {{Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.659644},
}
Figure